The S&P 500 has dropped below the crucial 5,700 mark and its 200-day moving average.
Tech giants are down 30-50% from their highs.
No one is safe from Washington's DOGE initiative. Just ask Accenture.
Tariff policies loom as another wild card for investors navigating increasingly choppy waters.
Yet opportunities remain for those who look past the headlines...
Dell and Hewlett-Packard present contrasting financial pictures despite similar market challenges. Krystal offers innovative gene therapy solutions at just 25x forward earnings with substantial upside potential.
The smart money knows that balance sheets matter more than ever... cash flow is king... and fundamental analysis separates the winners from the losers.
We're not just witnessing normal market fluctuations - we're at a decisive moment where preparation and perspective will determine who thrives in the months ahead.
As always, your Total Wealth team keeps its focus on what matters most for investors.
You can find our experts' latest guidance on the markets, what's likely to come next, and where investors should look now... below.
There's a unique strategy that crushed the S&P's relative return by 396% in 2024 when you look at all of the closed positions - winners and losers.
It's delivered gains of 100% in 21 days on Genco Shipping... 100% on Duke Energy in seven days .... and even an astonishing 250% in just three days on W.R. Berkley.
One man turned $4,900 into $13,400 on that WRB trade.
Another man called this strategy a "game changer."
Another gentleman said, "Not sure why I should make any other trades outside of [THIS]... I don't think I have lost any trades!"
Uncle Sam's diet plan is starving government contractors. Accenture's shocking 7% stock plunge is just the first casualty of Washington's new spending diet. Read more.
This biotech generates positive cash flow while others burn money. At 25x forward earnings, you're getting tomorrow's genetic breakthroughs at a discount. Watch here.
Markets fell below a critical threshold that legendary trader Paul Tudor Jones warns against. History shows trouble follows when it happens. Read more.
While everyone is chasing gold at $2,500 per ounce, there's a little-known investment that gives you exposure to over 1 oz of gold - for less than $20. And the best part? It has outperformed gold by 10-to-1 over the past 25 years.
You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here.
Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox.
Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.
Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.
No comments:
Post a Comment